1 / 6

Treatment of Chronic HCV Genotype 2 thru 6

Treatment of Chronic HCV Genotype 2 thru 6 . Treatment duration 24 weeks Ribavirin fixed dose – 800 mg/daily Currently HCV protease inhibitors are not approved to treat genotype 2 and 3 . Treatment: Genotype 2 and 3 Pegylated and Ribavirin (FDA Package Insert) .

marissa
Download Presentation

Treatment of Chronic HCV Genotype 2 thru 6

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treatment of Chronic HCV Genotype 2 thru 6 • Treatment duration 24 weeks • Ribavirin fixed dose – 800 mg/daily • Currently HCV protease inhibitors are not approved to treat genotype 2 and 3

  2. Treatment: Genotype 2 and 3Pegylated and Ribavirin (FDA Package Insert) • Merck /Schering – PEG-Intron + Rebetol (800-1400mg) • Genotype 2 thru 6 – 75% (48 weeks) • One large multi-international study • Genentech/Roche – Pegasys + Copegus (1000-1200 mg) • Genotype 2 & 3 – 82% SVR (24 weeks) • Genotype 2 thru 6 – 70% SVR (48 weeks) • Two large multi-international studies * Also approved to treat compensated cirrhosis, HIV/HCV Coinfection, Renal (mono) and HBV (mono)

  3. Treatment of HCV Genotype 1 • Only approved for chronic HCV genotype 1 • Treatment with an HCV protease inhibitor is only used in combination with pegylated interferon and ribavirin • The HCV protease inhibitors are taken every 7 to 9 hours with food: • Boceprevir – light meal / Telaprevir –not low fat

  4. Victrelis (Boceprevir)4-week lead in – Peg/Rbv treatment naïve – Genotype 1 Up to 66% SVR African Americans – up to 53% vs. 23% SVR Treatment duration either 28 or 48 weeks Treatment Experienced – Genotype 1 Prior non-responders–up to 66% SVR (null responders not studied) Treatment duration 36 or 48 weeks www.hcvadvocate.org

  5. Incivek (Telaprevir)Incivek, pegylated interferon, ribavirin taken for 12 weeks only—followed by pegylated interferon/ribavirin Treatment naïve – Genotype 1: Up to 79% SVR African American patients: 62% vs. 25% SVR People with cirrhosis: 62% vs. 33% SVR Treatment Experienced – genotype 1: Up to 86% SVR depending on type of non-response (relapsers, non-responders, null responders) *Treatment duration 24 or 48 weeks www.hcvadvocate.org

  6. Standard Protocol • Pegylated (injected once a week) • Ribavirin (pill or capsule – oral twice a day) with food • Victrelis / Incivek (pill—every 7 to 9 hours) for genotype 1 only with food • Treatment is guided by type of on-treatment response (week 4 and 12)

More Related